[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7-34. https://doi.org/10.3322/caac.21551.
[2] Leow JJ, Bedke J, Chamie K, et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019; 37 (1): 61-83. https://doi.org/10.1007/s00345-018-2606-y.
[3] Albisinni S, Rassweiler J, Abbou CC, et al. Long-term analysis of oncological outcomes after laparoscopic radical cystectomy in Europe: results from a multicentre study by the European Association of Urology (EAU) section of Uro-technology. BJU Int. 2015; 115(6): 937-945. https://doi.org/10.1111/bju.12947.
[4] Patel MI, Bang A, Gillatt D, et al. Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study. BJU Int. 2015; 116 Suppl 3: 18-25. https://doi.org/10.1111/bju.13152.
[5] Zehnder P, Studer UE, Skinner EC, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 2013; 112(2): E51-58. https://doi.org/10.1111/bju.12215.
[6] Magers MJ, Lopez-Beltran A, Montironi R, et al. Staging of bladder cancer. Histopathology. 2019; 74(1): 112-134. https://doi.org/10.1111/his.13734.
[7] Kluth LA, Black PC, Bochner BH, et al. Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol. 2015; 68(2): 238-253. https://doi.org/10.1016/j.eururo.2015.01.032.
[8] Shariat SF, Karakiewicz PI, Palapattu GS, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006; 12(22): 6663-6676. https://doi.org/
[9] Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after raical cystectomy. Eur Urol. 2007; 51(1): 137-149. https://doi.org/10.1158/1078-0432.CCR-06-0372.
[10] Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006; 42(6): 760-767. https://doi.org/10.1016/j.ejca.2006.01.002.
[11] Gakis G. The role of inflammation in bladder cancer. Adv Exp Med Biol. 2014; 816: 183-196. https://doi.org/10.1007/978-3-0348-0837-8_8.
[12] Temraz S, Mukherji D, Farhat ZA, et al. Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol. 2014; 14: 76. https://doi.org/10.1186/1471-2490-14-76.
[13] Zhang GM, Zhu Y, Luo L, et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumour Biol. 2015; 36(11): 8537-8543. https://doi.org/10.1007/s13277-015-3613-x.
[14] Yoshida T, Kinoshita H, Yoshida K, et al. A novel risk stratification model, involving preoperative lymphocyte-monocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy. Jpn J Clin Oncol. 2015; 45(12): 1162-1167. https://doi.org/10.1093/jjco/hyv146.
[15] Yoshida T, Kinoshita H, Yoshida K, et al. Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy. Tumor Biol. 2016; 37(8): 10067-10074. https://doi.org/10.1007/s13277-016-4874-8.
[16] Rajwa P, Życzkowski M, Paradysz A, et al. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci. 2018; 22(10): 3027-3037. https://doi.org/10.26355/eurrev_201805_15060.
[17] D’Andrea D, Moschini M, Gust KM, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol. 2017; 115(4): 455-461. https://doi.org/10.1002/jso.24521.
[18] Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003; 95(9): 634-635. https://doi.org/10.1093/jnci/95.9.634.
[19] Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26(6): 565-574. https://doi.org/10.1177/0272989X06295361.
[20] Shariat SF, Svatek RS, Tilki D, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010; 105(10): 1402-1412. https://doi.org/10.1111/j.1464-410X.2010.09217.x.
[21] Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4): 361-387. https://doi.org/10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.
[22] Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001; 54(8): 774-781. https://doi.org/10.1016/s0895-4356(01)00341-9.
[23] Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2): 337-344. https://doi.org/10.1111/j.0006-341x.2000.00337.x.
[24] Kang L, Chen W, Petrick NA, et al. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015; 34(4): 685-703. https://doi.org/10.1002/sim.6370.
[25] Viers BR, Boorjian SA, Frank I, et al. Pretreatment neutrophoil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014; 66(6): 1157-1164. https://doi.org/10.1016/j.eururo.2014.02.042.
[26] Hutterer GC, Sobolev N, Ehrlich GC, et al. Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma. J Clin Pathol. 2015; 68(5): 351-355. https://doi.org/10.1136/jclinpath-2014-202658.
[27] Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014; 110(2): 435-440. https://doi.org/10.1038/bjc.2013.785.
[28] Hai B, Ya T, Chuan S, Jiarui L, Tingting L, Zhen C, Chen C, Yi H, Yuanyuan Z. Urinary microbiota—a potential biomarker and therapeutic target for bladder cancer. J Med Microbiol, 2019; 68(10): 1471-1478. https://doi.org/10.1099/jmm.0.001058.
[29] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6): 883-899. https://doi.org/10.1016/j.cell.2010.01.025.
[30] Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1): 71-78. https://doi.org/10.1038/nrc1256.
[31] Joseph M, Enting D. Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front Oncol. 2019; 9: 1270. https://doi.org/10.3389/fonc.2019.01270.
[32] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008; 454(7203): 436-444. https://doi.org/10.1038/nature07205.
[33] Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019; 16(10): 613-630. https://doi.org/10.1038/s41585-019-0226-y.
[34] Wang B, Wu S, Zeng H, et al. CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol. 2015; 194(2): 556-562. https://doi.org/10.1016/j.juro.2015.02.2941.
[35] Ma JY, Hu G, Liu Q. Prognostic significance of the lymphocyte-to-monocyte ratio in bladder cancer undergoing radical cystectomy: a meta-analysis of 5638 individuals. Dis Markers. 2019; 2019: 7593560. https://doi.org/10.1155/2019/7593560.